Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d supply of clinical material until transfer of manufacturing.

TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and recently received approval to enter a Phase Ib dose escalation trial. This Phase Ib trial will be conducted in patients with advanced cancer and is due to commence shortly in Denmark.

TB-403 has the potential to be a major advance in the treatment of cancer. It is a humanized monoclonal antibody that blocks the formation of the new blood vessels that are needed by solid tumours to support their growth. TB-403 has the potential to minimize both the growth and spread of cancer cells.

Professor Désiré Collen, CEO and Chairman of ThromboGenics, said: "TB-403 has generated a great deal of interest from the pharmaceutical community. Therefore, we are delighted that we have signed this major licensing agreement with Roche, given their expertise and success in bringing novel anti-cancer agents to the market. This deal represents a significant milestone in ThromboGenics' development as a company. It also reflects TB-403's potential as a promising treatment for cancer, and is a testament to the hard work and high quality science on which ThromboGenics' business is based. The funding from this deal also gives us the financial resources to continue to build our strong pipeline. We look forward to working with Roche, and to the successful development of this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, commented on the deal: "We believe that TB-403 has great potential for the treatment of cancer, with its unique mode of action targeting PlGF, and are delighted that Roche has recognised this potential. This agreement demonstrates our ability to identify innovative projects and to realize the clinical potential of a therapeutic antibody. We look forward to seeing the product progress further through clinical development and towards market."

Dan Zabrowski, Global Head of Pharma Partnering, Roche adde
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2008)...ieve undetectable HCV RNA levels, following 4 week...R) plus Copegus(R) -,...dministered with Pegasys ...wswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VR...th cohort of a,4-week Phase 1 proof-of-concept cli...
(Date:9/8/2008)...ement Consulting announced that it has appointed A... Charlotte, NC (PRWEB) September 8, 2008...ment Consulting] announced that it has appointed A...len joins Symphony from Wellesley Information Serv... developing, and producing national educational co...
(Date:9/6/2008)...elps visitors to electronica 2008 in Munich and co...ctronica information available on the visitor hotl...nning a trip, online registration benefits, a summ...ludes an extensive list of web links to travel, ho... Munich, Germany (PRWEB) September 6, 2008 -...
(Date:9/5/2008)...stitute of Standards and Technology (NIST) and Seo...weak a new class of polymer-based semiconductors t... components of the blend. Their recent resultshow ...gn of practical, large-scale manufacturing techniq...onic displays and other devices.* , Organic semi...
Breaking Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3Bottoms up: Better organic semiconductors for printable electronics 2
...Neurognostics, Inc. , a Wisconsin company speciali...I) products and services, has been honored with a ...tanding Achievements. , ,Last year Neurognostics r...ch (SBIR) Grant from the National Institutes of He...RI-based biomarkers in Parkinson,s disease. Neurog...
... GE Healthcare,s LightSpeed VCT, the world,s firs...gnized today by the Wall Street Journal in the M... Technology Innovation Awards. The annual awards r...s, companies and organizations around the world in...e Wall Street Journal received approximately 750 a...
...rent Energy Systems, Inc. announced today that Dr...Dr. Raman is President of Protium Energy Technolo...gen, fuel cells and alternative energy, based in A..., Inc., is developing Aqueous Phase Reforming (APR...fuel gases and other high value chemicals. APR us...
... Wis.— Renaissance Learning , Inc., a provi...ring tools for pre-K-12 schools and districts, wil...raining and certification office center for all Re...also plans to adjust space needs at other faciliti...s Wisconsin Rapids operation. , ,As part of its Al...
Other Biology Technology:
(Date:9/8/2008)...lif., September 8, 2008For allergy sufferers, the ...without pets or curtains or anything that could tr... extends its Anywhere® product line with the l...abric Spray, a new product to help manage indoor a...rox® Anywhere® Anti-Allergen Fabric Spray ...
(Date:9/8/2008)..., September 2, 2008 -- A new interactive web lesso...raduate students how herbicides are developed. The...te University, has the seal of approval by the Jo...tion and is published in the 2008 issue. , Surp...et today were discovered by random searching. Coll...
(Date:9/7/2008)...s ability to sweat may do more than keep the body ...ise-induced asthma (EIA), a common respiratory con...ing in the September issue of CHEST, the peer-re...ysicians (ACCP), shows that athletes with EIA prod...o not have breathing problems. , Warren Lockett...
(Date:9/7/2008)...A Even closely related plants produce their own n...ed to the individual plant,s specific habitat. Com...e, researchers at the Salk Institute for Biologica...a key enzyme are enough to shift the whole output ...hanges led to a mixture of henbane and tobacco-spe...
Breaking Biology News(10 mins):The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Athletes' 'sweat and tears' linked to asthma 2Athletes' 'sweat and tears' linked to asthma 3How plants fine tune their natural chemical defenses 2How plants fine tune their natural chemical defenses 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 1Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 7Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 1Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 2Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 3VaxGen Issues Rebuttal to MedCap Letter 4156 1VaxGen Issues Rebuttal to MedCap Letter 4156 2VaxGen Issues Rebuttal to MedCap Letter 4156 3VaxGen Issues Rebuttal to MedCap Letter 4156 4VaxGen Issues Rebuttal to MedCap Letter 4156 5VaxGen Issues Rebuttal to MedCap Letter 4156 6VaxGen Issues Rebuttal to MedCap Letter 4156 7VaxGen Issues Rebuttal to MedCap Letter 4156 8VaxGen Issues Rebuttal to MedCap Letter 4156 9VaxGen Issues Rebuttal to MedCap Letter 4156 10VaxGen Issues Rebuttal to MedCap Letter 4156 11Tempo Participacoes S A Announces Increase of 16 8 25 in Net Revenue and of 46 3 25 in EBITDA for 2007 15024 1
... be frighteningly large if only there was a greate...concludes. The study adds support to the theory th...aleozoic period because they had a much richer oxy... Kaiser. , The study, "No giants today: tracheal o...l be presented Oct. 10 and 11 at Comparative Physi...
...rve pain ?by aiming drugs at a previously unrecogn...ersity of Utah scientists who study the venoms of ...new way to treat a chronic and debilitating form o...on Earth," says J. Michael McIntosh, a University ...h director and professor in the Department of Psyc...
...ohn Shelnutt and Yujiang Song have discovered a be...rough a new process that produces novel hollow pla...s a paper in an upcoming issue of the German chemi...of publication, it is featured as a short "hot pap...ional Nuclear Security Administration laboratory. ...
...ans diverged from a common ancestor and evolved in...ified a new way to pinpoint the genes that separat... uniquely human. The Proceedings of the National ...13 online edition. , "We share more than 95 perc...ed Dr. Daniel Geschwind, principal investigator an...
Other Biology News:Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3A new target for painkillers 2A new target for painkillers 3A new target for painkillers 4Sandia researchers discover way to see how a drug attaches to a cell 2Unraveling where chimp and human brains diverge 2
...it Polyclonal to Human CELSR3 CELSR3 is an Orpha...ene is expressed during development at sites of ac...ain, spinal cord, dorsal root ganglion, and eye. E...is, blood, brain, colon, heart/melanocyte/uterus, ...
...ination inline heater plus multi-channel focal dru...ug wash-out with a high-flow bath line while quick...e Perfusion Pencil.® Steady 37°C at 5 ml/...ip. Advanced auto-tuning temperature lock Desig...
Immunogen: purified recombinant human angiogenin expressed in E. coli . Physical form: Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline. Titertest method: ELISA (c).
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da
Biology Products: